ストックスクリーナーアプリを入手
2.86
11.18%
-0.36
前日終値:
$3.22
開ける：
$3.19
24時間の取引高:
1.96M
Relative Volume:
2.14
時価総額：
$586.95M
収益：
-
当期純損益:
$-54.70M
株価収益率:
-8.6667
EPS:
-0.33
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
-15.88%
1か月 パフォーマンス:
+4.38%
6か月 パフォーマンス:
-27.96%
1年 パフォーマンス:
-43.59%
1日の値動き範囲:
$2.85
$3.33
1週間の範囲:
$2.805
$3.558
52週間の値動き範囲:
$2.31
$5.11
Savara Inc Stock (SVRA) Company Profile
SVRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.86 | 586.95M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Wells Fargo & Company MN Has $182,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Sold by MetLife Investment Management LLC - Defense World
Analysts Set Savara Inc (NASDAQ:SVRA) Target Price at $8.83 - Defense World
Barclays PLC Grows Stake in Savara Inc (NASDAQ:SVRA) - Defense World
Metric Deep Dive: Understanding Savara Inc (SVRA) Through its Ratios - DWinneX
Raymond James Financial Inc. Buys Shares of 259,798 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
A stock that deserves closer examination: Savara Inc (SVRA) - uspostnews.com
Savara Announces Participation in the Upcoming Citizens Life Sciences Conference - Business Wire
Legal & General Group Plc Sells 12,613 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Savara Inc (NASDAQ:SVRA) Shares Purchased by Geode Capital Management LLC - Defense World
JMP maintains $10 target on Savara stock post-BLA submission By Investing.com - Investing.com Nigeria
Examining Savara Inc (SVRA) more closely is necessary - uspostnews.com
JMP maintains $10 target on Savara stock post-BLA submission - Investing.com
Savara: Make-It-Or-Break-It Molbreevi BLA Filing (NASDAQ:SVRA) - Seeking Alpha
Savara Inc. Announces Equity Awards for New Employees - MSN
JPMorgan Chase & Co. Grows Stock Position in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ:SVRA) Shares Purchased by Vanguard Group Inc. - Defense World
Corebridge Financial Inc. Sells 4,330 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
KLP Kapitalforvaltning AS Purchases Shares of 13,200 Savara Inc (NASDAQ:SVRA) - Defense World
Savara Announces New Employment Inducement Grant | SVRA Stock Ne - GuruFocus
Savara Announces New Employment Inducement Grant - Enidnews.com
Savara's Bold Move: 190K Share Grant Signals Aggressive Growth Strategy - Stock Titan
Savara Inc (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara to present aPAP treatment study at medical congresses By Investing.com - Investing.com Canada
Savara to present aPAP treatment study at medical congresses - Investing.com
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences - MarketScreener
Breakthrough Phase 3 Results: New Treatment Could Transform Rare Lung Disease Management - Stock Titan
259,798 Shares in Savara Inc (NASDAQ:SVRA) Bought by Raymond James Financial Inc. - Defense World
Raymond James Financial Inc. Invests $798,000 in Savara Inc (NASDAQ:SVRA) - The AM Reporter
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt? - simplywall.st
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - marketscreener.com
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com South Africa
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):